Fast Five Quiz: Molecular and Biomarker Analysis in Non–Small Cell Lung Cancer (NSCLC)

Daniel S. Schwartz, MD


January 28, 2022

International guidelines jointly published in 2018 by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology, recommend that all patients with lung adenocarcinomas should be tested for genetic abnormalities that indicate suitability for treatment with targeted agents, regardless of clinical variables such as sex, ethnicity, or smoking status. Molecular and biomarker analysis may include:

Learn more about molecular and biomarker analysis in NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.